Vol. 2 No. 7 (2022)
Reimbursement Recommendations

Selpercatinib (Retevmo)

Published July 18, 2022

Key Messages

  • CADTH recommends that Retevmo be reimbursed by public drug plans for the treatment of adults with advanced or metastatic rearranged during transfection (RET) fusion-positive differentiated thyroid cancer (DTC) if certain conditions are met.
  • Retevmo should only be covered to treat patients who have advanced or metastatic DTC (not amenable to surgery or radioactive iodine therapy) with the RET mutation and have had prior treatment with sorafenib and/or lenvatinib. Patients receiving Retevmo should be in relatively good health (i.e., have a good performance status, as determined by a specialist).
  • Retevmo should only be reimbursed if it is prescribed by a specialist, the patients' cancer is RET positive, it is not given in combination with other anticancer drugs, and the price is reduced.